Efficacy of Anti-Tumor Necrosis Factor-[alpha] Therapy Against Intestinal Behcet's Disease Complicated by Recurrent Enterocutaneous Fistulae

A 55-year-old man presented with recurrent ulcers and an enterocutaneous fistula at the anastomotic site after surgery for an ileovesical fistula and was diagnosed with intestinal Behcet's disease after undergoing surgery for enterocutaneous fistulae twice. The patient was transferred to our ho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biologics 2022-02, Vol.16, p.1
Hauptverfasser: Kashima, Hitomi, Matsumoto, Satohiro, Kojima, Shu, Koito, Yudai, Miura, Takaya, Ishii, Takehiro, Mashima, Hirosato
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A 55-year-old man presented with recurrent ulcers and an enterocutaneous fistula at the anastomotic site after surgery for an ileovesical fistula and was diagnosed with intestinal Behcet's disease after undergoing surgery for enterocutaneous fistulae twice. The patient was transferred to our hospital because of recurrent enterocutaneous fistulae. He had a history of recurrent oral aphthous ulcers, folliculitis, and epididymitis and met the diagnostic/classification criteria for incomplete Behcet's disease and thus was diagnosed as having intestinal Behcet's disease. Remission induction therapy with steroids was administered for an ileal ulcer and an enterocutaneous fistula, and adalimumab was initiated for maintenance therapy. The fistula was closed, and the clinical course was favorable. Two months after initiating adalimumab, a subcutaneous abscess was detected at the site of the enterocutaneous fistula scar, and relapse of intestinal Behcet's disease was suspected. Steroids were re-administered for remission induction, followed by maintenance therapy, for which adalimumab was switched to infliximab. No relapse was detected after steroid withdrawal. No therapeutic strategies have been established for intestinal Behcet's disease. Moreover, there have been very few reports on therapeutic strategies and postoperative maintenance therapy for enterocutaneous fistulae. We thus consider this case valuable. Keywords: intestinal Behcet's disease, adalimumab, infliximab, enterocutaneous fistulae
ISSN:1177-5475
DOI:10.2147/BTT.S348300